National surgical adjuvant breast and bowel project update: Prevention trials and endocrine therapy of ductal carcinoma in situ

Clinical Cancer Research

Volumn 9, Issue 1 II, 2003, Pages

  Vogel, Victor G ^b   Costantino, Joseph P ^a   Wickerham, D Lawrence ^a   Cronin, Walter M ^a  

^a NSABP Foundation Inc   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; PLACEBO; RALOXIFENE; TAMOXIFEN;

ADULT; AGED; BREAST CARCINOMA; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CARCINOMA IN SITU; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; META ANALYSIS; PARTIAL MASTECTOMY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, LOBULAR; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MASTECTOMY; RALOXIFENE; RANDOMIZED CONTROLLED TRIALS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 12244299196     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (26)

1. Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., Daly, M., Wieand, S., Tan-Chiu, E., Ford, L., Wolmark, N., and other National Surgical Adjuvant Breast and Bowel Project Investigators. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. (Bethesda), 90: 1371-1388, 1998.
2. Gail, M. H., Costantino, J. P., Bryant, J., Croyle, R., Freedman, L., Helzlsouer, K., and Vogel, V. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J. Natl. Cancer Inst. (Bethesda), 91: 1829-1846, 1999.
3. Ettinger, B., Black, D. M., Mitlak, B. H., Knickerbocker, R. K., Nickelsen, T., Genant, H. K., Christiansen, C., Delmas, P. D., Zanchetta, J. R., Stakkestad, J., Glüer, C. C., Krueger, K., Cohen, F. J., Eckert, S., Ensrud, K. E., Avioli, L. V., Lips, P., and Cummings, S. R. for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. J. Am. Med. Assoc., 282: 637-645, 1999.
4. Cummings, S. R., Eckert, S., Krueger, K. A., Grady, D., Powles, T. J., Cauley, J. A., Norton, L., Nickelsen, T., Bjarnason, N. H., Morrow, M., Lippman, M. E., Black, D., Glusman, J. E., Costa, A., and Jordan, V. C. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. J. Am. Med. Assoc., 281: 2189-2197, 1999.
5. Gail, M. H., Brinton, L. A., Byar, D. P., Corle, D. K., Green, S. B., Schairer, C., and Mulvihill, J. J. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J. Natl. Cancer Inst. (Bethesda), 81: 1879-1886, 1989.
6. Costantino, J. P., Gail, M. H., Pee, D., Anderson, S., Redmond, C. K., Benichou, J., and Wieand, H. S. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J. Natl. Cancer Inst. (Bethesda), 91: 1541-1548, 1999.
7. Dupont, W. D., Page, D. L., Parl, F. F., Vnencak-Jones, C. L., Plummer, W. D., Jr., Rados, M. S., and Schuyler, P. A. Long-term risk of breast cancer in women with fibroadenoma. N. Engl. J. Med., 331: 10-15, 1994.
8. Fabian, C. J., Kimler, B. F., Zalles, C. M., Klemp, J. R., Kamel, S., Zeiger, S., and Mayo, M. S. Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model. J. Natl. Cancer Inst. (Bethesda), 92: 1217-1227, 2000.
9. Yeomans-Kinney, A. C., Vernon, S. W., Weber, D. M., Bitsura, J. M., and Vogel, V. G. Factors related to enrollment in the Breast Cancer Prevention Trial at a comprehensive cancer center during the first year of recruitment. Cancer (Phila.), 76: 46-56, 1995.
10. Kinney, A. Y., Richards, C., Vernon, S. W., and Vogel, V. G. The effect of physician recommendation on enrollment in the Breast Cancer Chemoprevention Trial. Prev. Med., 27: 713-719, 1998.
11. Day, R., Ganz, P. A., Costantino, J. P., Cronin, W. M., Wickerham, D. L., and Fisher, B. Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Clin. Oncol., 17: 2659-2669, 1999.
12. Day, R., Ganz, P. A., and Costantino, J. P. Tamoxifen and depression: more evidence from the National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention (P-1) Randomized Study. J. Natl. Cancer Inst. (Bethesda), 93: 1615-1623, 2001.
13. Narod, S. A., Brunet, J. S., Ghadirian, P., Robson, M., Heimdal, K., Neuhausen, S. L., Stoppa-Lyonnet, D., Lerman, C., Pasini, B., de los Rios, P., Weber, B., and Lynch, H. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet, 356: 1876-1881, 2000.
14. Verhoog, L. C., Brekelmans, C. T. M., Seynaeve, C., Dahmen, G., van Geel, A. N., Bartels, C. C. M., Tilanus-Linthorst, M. M. A., Wagner, A., Devilee, P., Halley, D. J. J., van den Ouweland, A. M. W., Meijers-Heijboer, E. J., and Klijn, J. G. M. Survival in hereditary breast cancer associated with germline mutations of BRCA2. J. Clin. Oncol., 17: 3396-3402, 1999.
15. King, M-C., Wieand, S., Hale, K., Lee, M., Walsh, T., Owens, K., Tait, J., Ford, L., Dunn, B. K., Costantino, J., Wickerham, D. L., Wolmark, N., and Fisher, B. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2. National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. J. Am. Med. Assoc., 286: 2251-2256, 2001.
16. IBIS Investigators. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet, 360: 817-824, 2002.
17. Buzdar, A., Jonat, W., Howell, A., Jones, S. E., Blomqvist, C., Vogel, C. L., Eiermann, W., Wolter, J. M., Azab, M., Webster, A., and Plourde, P. V. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two Phase III trials. Arimidex Study Group. J. Clin. Oncol., 14: 2000-2011, 1996.
18. Nabholtz, J. M., Buzdar, A., Pollak, M., Harwin, W., Burton, G., Mangalik, A., Steinberg, M., Webster, A., and von Euler, M. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J. Clin. Oncol., 18: 3758-3767, 2000.
19. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet, 359: 2131-2139, 2002.
20. Cuzick, J. Future possibilities in the prevention of breast cancer: breast cancer prevention trials. Breast Cancer Res., 2: 258-263, 2000.
21. Fisher, B., Dignam, J., Wolmark, N., Wickerham, D. L., Fisher, E. R., Mamounas, E., Smith, R., Begovic, M., Dimitrov, N. V., Margolese, R. G., Kardinal, C. G., Kavanah, M. T., Fehrenbacher, L., and Oishi, R. H. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet., 353: 1993-2000, 1999.
22. Fabian, C. J., and Kimler, B. F. Beyond tamoxifen: new endpoints for breast cancer chemoprevention, new drugs for breast cancer prevention. Ann, N. Y. Acad. Sci., 952: 44-59, 2001.
23. Chlebowski, R., Col, N., Weiner, E., Collyar, D., Cummings, S., Vogel, V., Eisen, A., Lipkus, I., and Pfister, D., for the ASCO Breast Cancer Technology Assessment Working Group. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J. Clin. Oncol., 20: 3328-2243, 2002.
24. United States Preventive Services Task Force. Chemoprevention of breast cancer: recommendation and rationale. Ann. Intern. Med., 137: 56-58, 2002.
25. Kinsinger, L. S., Harris, R., Woolf, S. H., Sox, H. C., and Lohr, K. N. Chemoprevention of breast cancer: a summary of the evidence for the U. S. Preventive Services Task Force. Ann. Intern. Med., 137: 59-67, 2002.
26. Vogel, V. G. Chemoprevention: reducing breast cancer risk. In: V. G. Vogel (ed.), Management of Patients at High Risk for Breast Cancer, pp. 201-227. Malden, MA: Blackwell Science, Inc., 2001.